TLR3 and uveitis: developed phosphorylatable short peptide‐conjugated CS (pSP‐CS) for the targeted delivery of TLR3 siRNA (Figure 7C), specifically inhibiting TLR3 in RPE cells in vitro.[294] The administration of pSP‐CS/TLR3‐siRNA resulted in reduced inflammatory cell infiltration and preserved retinal structure, as revealed by H&E staining, which led to a decrease in the severity of uveitis.